<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224949</url>
  </required_header>
  <id_info>
    <org_study_id>17-718</org_study_id>
    <nct_id>NCT03224949</nct_id>
  </id_info>
  <brief_title>Comparison of ALD, NASH, and Healthy Control Patients</brief_title>
  <official_title>Comparison of ALD, NASH, and Healthy Control Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The availability of biological samples from individuals with alcoholic liver disease (ALD),&#xD;
      as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking&#xD;
      healthy controls, is an essential first step in the translation of basic research advances to&#xD;
      the clinic. The purpose of the Clinical Core component of the P50 Northern Ohio Alcohol&#xD;
      Center (NOAC) is to provide biological samples (plasma/serum, buffy coats, and urine) from&#xD;
      patients with different stages of alcoholic liver disease, as well as healthy control&#xD;
      subjects, to members of the NOAC. These samples can then be used to test specific hypotheses&#xD;
      related to the presence of specific biomarkers in the serum, functional immune activity in&#xD;
      PBMCs and/or genetic polymorphisms that may predict severity of disease, short- and long-term&#xD;
      morbidity and mortality and/or responsivity to specific therapeutic interventions commonly&#xD;
      used in clinical practice. This study is building on the established biorepositories and the&#xD;
      diversity of outstanding clinical expertise at the Cleveland Clinic. This biorepository&#xD;
      included clinical samples (plasma, serum, buffy coats, and urine) from patients with&#xD;
      different stages of ALD and subjects who are heavy drinkers without ALD, recruited from the&#xD;
      Cleveland Clinic alcohol use disorder treatment clinic. This study will be responsible for&#xD;
      collecting more data to help build the CCF-ALD biorepository via subject recruitment and&#xD;
      communication and specimen collection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biorepository</measure>
    <time_frame>This is a 5 year study</time_frame>
    <description>The goal of this study is to create a biorepository of samples from patients with different types of liver disease compared to each other and healthy controls</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>ALD - Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcoholic hepatitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcoholic steatosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcoholic cirrhosis without HCC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonalcoholic steatohepatitis (NASH)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcoholic cirrhosis with HCC</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Patients will have a one time blood draw</description>
    <arm_group_label>Alcoholic cirrhosis with HCC</arm_group_label>
    <arm_group_label>Alcoholic cirrhosis without HCC</arm_group_label>
    <arm_group_label>Alcoholic hepatitis</arm_group_label>
    <arm_group_label>Alcoholic steatosis</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Nonalcoholic steatohepatitis (NASH)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from within Cleveland Clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Alcoholic Steatosis Patients&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
          -  Fat accumulation (Steatosis) without signs of fibrosis/ inflammation in patients with&#xD;
             alcohol abuse (alcohol intake &gt;60 g/day in men and &gt;40 g/day in women)&#xD;
&#xD;
          -  Abnormal liver serum tests indicative of liver disease (elevated AST&gt;ALT, y-glutamyl&#xD;
             transpeptidase and bilirubin) .&#xD;
&#xD;
        Alcoholic Hepatitis with Mild Fibrosis&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
          -  Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular&#xD;
             ballooning)&#xD;
&#xD;
          -  Polymorphonuclear infiltrate&#xD;
&#xD;
          -  Fibrosis stage 1-2&#xD;
&#xD;
        Alcoholic Hepatitis with Advanced Fibrosis&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
          -  Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular&#xD;
             ballooning)&#xD;
&#xD;
          -  Polymorphonuclear infiltrate&#xD;
&#xD;
          -  Fibrosis stage 3-4.&#xD;
&#xD;
        Alcoholic Cirrhosis&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
          -  Fibrosis stage 4&#xD;
&#xD;
          -  Presence of complications of cirrhosis such as esophageal varices with our without a&#xD;
             previous episode of bleeding, splenomegaly, ascites, hepatic corroborate the diagnosis&#xD;
             of cirrhosis.&#xD;
&#xD;
        Alcoholic Cirrhosis with HCC&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
        -Diagnostic criteria of cirrhosis and established HCC. The diagnosis of HCC will be&#xD;
        established based on histological confirmation or contrast-enhanced radiographic imaging&#xD;
        according to the AASLD recommendations.&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  BMI&gt;35&#xD;
&#xD;
          -  HBV&#xD;
&#xD;
          -  Hemochromatosis&#xD;
&#xD;
          -  Wilson's disease&#xD;
&#xD;
          -  Autoimmune hepatitis&#xD;
&#xD;
          -  Drug-inducted liver disease&#xD;
&#xD;
          -  Hepatitis C&#xD;
&#xD;
          -  Antitrypsin deficiency&#xD;
&#xD;
          -  Patients who do not sign informed consent.&#xD;
&#xD;
        Non-alcoholic steatohepatitis&#xD;
&#xD;
        Inclusion -Biopsy proven NASH and chronic liver disease due to HCV patients.&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  CAD or stroke&#xD;
&#xD;
          -  Past history of liver disease&#xD;
&#xD;
          -  Hepatitis C&#xD;
&#xD;
          -  Antitrypsin deficiency&#xD;
&#xD;
          -  Alcohol consumption of less than 7 drinks per week for women and less than 14 drinks&#xD;
             per week for men&#xD;
&#xD;
          -  BMI &gt;35.&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
        Inclusion&#xD;
&#xD;
        -AUDIT-C score less than 4 in men and less than 3 in women.&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Cancer (except of non-melanoma skin cancer)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Hypercholesterolemia&#xD;
&#xD;
          -  Coronary artery disease or stroke&#xD;
&#xD;
          -  History of current or past liver disease of any etiology&#xD;
&#xD;
          -  BMI &gt;27Kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivisan Dasarathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staff</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annette Bellar, MSLA</last_name>
    <phone>216-636-5247</phone>
    <email>bellara@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Revathi Penumatsa, MD</last_name>
    <phone>216 445-0688</phone>
    <email>penumar@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Bellar, BS</last_name>
      <phone>216-636-5247</phone>
      <email>bellara@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan Villareal, BS</last_name>
      <phone>216-636-5247</phone>
      <email>villarm@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Srinivasan Dasarathy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Srinivasan Dasarathy</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

